🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Totally agree w Richard Finn that Emerald-1 is NOT practice changing - w a PFS HR of 0.77 and OS 0.94 (no dif). Also great slide/figure on threshold of PFS HR needed to be considered appropriate surrogate endpoint for OS in HCC. HCC-LIVE Conference

nature.com/articles/s4159…

👎Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial pubmed.ncbi.nlm.nih.gov/38395969/

Live from #ASCO24 #GE and #HPB Track🔥🔥 ☑️IKF-575/RENAISSANCE ➡️Systemic therapy+/- Surgery in Limited Metastatic Gastric/GEJ Cancers by Salah-Eddin Al-Batran ☑️Surgery after 4 cycles of FLOT 🔪💉 ☑️Improved OS in RPLN⬆️⬆️ ❎Detrimental in Peritoneal Mets🔽🔽 🧐Over 7 years

CheckMate 9DW by Robert Galle Nivo+Ipi- vs Lenva/Sorafenib in 1st line uHCC ⬆️A significant OS benefit (23.7 vs 20.6 months) ✅Consistent benefit in subgroup analyses ✅Reduced risk of symptom deterioration A new SOC in uHCC 👏 #ASCO24 #OncoAlertAF #Checkmate9DW OncoAlert

A very informative review about the value of RFS & PFS as trustable endpoints to capture survival benefit. They are vulnerable and raise thrill that may turn into deception. Important for liver cancer trials EASLnews AASLD ESMO - Eur. Oncology Conquer Cancer, the ASCO Foundation thelancet.com/journals/eclin…

#hacettepe #onkoloji2024 #saglik onkoloji2024.org

Arndt Vogel JHEP Reports ESMO - Eur. Oncology EASL Education ILCA Please also consider this data, also hot off the press: EBRT vs TACE Local control: HR 0.16 (0.08-0.34) PFS: HR 0.37 (0.23-0.60) OS: HR 0.52 (0.26-1.02) TACE is a poor option, we can do much better with SBRT! Freddy E Escorcia (@freddyeescorcia elsewhere) Jeff Ryckman Neil Newman redjournal.org/article/S0360-…

First meeting of the ESMO Virtual Mentorship Programme with Jon Lim, MRCP PhD. I’m deeply honored to be paired with Jon Lim, MRCP PhD as my mentor and can’t wait to learn and grow. Excellent initiative from ESMO - Eur. Oncology. #mentorship #mentors #ESMOYOC

A pleasure to be hosted by super Matteo Lambertini, MD PhD Marco Tagliamento in Genova for a preceptorship 💯💯 Fantastic programme and great hospitality for our group from 🇹🇷🇹🇷 Excited to have further collaborations together 🤓🤓 Special thanks to İsmail Çelik and Sandoz 💉💉 Onur Baş, MD

An important initiative by #ESMOYOC facilitating the research activities for YOs 🤓🤓 Congrats our previous #ESMOYOC chair super Matteo Lambertini, MD PhD and Angelika Starzer and all team💯💯 Grateful to be a part of the process ESMO - Eur. Oncology Rodrigo Sánchez-Bayona

📌Happy to share our perspective on uveal melanoma management, just out in ESMO Open With this amazing team Maurício Ribeiro, MD Ian Hirsch 🔗 esmoopen.com/article/S2059-…

Toni Choueiri, MD ATOMIC vs NICHE-2: 6 months of adjuvant FOLFOX plus 12 months of Atezo vs 2 doses of IO (1 Nivo/Ipi, 1 Nivo) followed by surgery within 6 weeks… which approach should we prefer?

Honored and humbled to receive the ASCO 2025 IDEA Award 🏆 Heartfelt thanks to my mentors and colleagues at Hacettepe University. Grateful to join #ASCO2025 among inspiring minds from around the world🌎 Deniz Can Guven Conquer Cancer, the ASCO Foundation ASCO

Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP) #ASCO25 👉Enhanced prognostic prediction 👉Robust validation ESMO - Eur. Oncology